Gene therapy for a mouse model of glucose transporter-1 deficiency syndrome

Sachie Nakamura, Hitoshi Osaka, Shin ichi Muramatsu, Naomi Takino, Mika Ito, Shiho Aoki, Eriko F. Jimbo, Kuniko Shimazaki, Tatsushi Onaka, Sumio Ohtsuki, Tetsuya Terasaki, Takanori Yamagata

Research output: Contribution to journalArticlepeer-review

9 Citations (Scopus)


Objective We generated an adeno-associated virus (AAV) vector in which the human SLC2A1 gene was expressed under the synapsin I promoter (AAV-hSLC2A1) and examined if AAV-hSLC2A1 administration can lead to functional improvement in GLUT1-deficient mice. Methods AAV-hSLC2A1 was injected into heterozygous knock-out murine Glut1 (GLUT1+/−) mice intraperitoneally (systemic; 1.85 × 1011 vg/mouse) or intra-cerebroventricularly (local; 1.85 × 1010 vg/mouse). We analyzed GLUT1 mRNA and protein expression, motor function using rota-rod and footprint tests, and blood and cerebrospinal fluid (CSF) glucose levels. Results Vector-derived RNA was detected in the cerebrum for both injection routes. In the intra-cerebroventricular injection group, exogenous GLUT1 protein was strongly expressed in the cerebral cortex and hippocampus near the injection site. In the intraperitoneal injection group, exogenous GLUT1 protein was mildly expressed in neural cells throughout the entire central nervous system. The motor function test and CSF/blood glucose ratio were significantly improved following intra-cerebroventricular injection. Conclusions AAV-hSLC2A1 administration produced exogenous GLUT1 in neural cells and improved CSF glucose levels and motor function of heterozygous knock-out murine Glut1 mice.

Original languageEnglish
Pages (from-to)67-74
Number of pages8
JournalMolecular Genetics and Metabolism Reports
Publication statusPublished - 2017 Mar 1


  • Adeno-associated virus (AAV)
  • GLUT1
  • Gene therapy
  • Glucose transporter I deficiency syndrome (GLUT1DS)
  • SLC2A1

ASJC Scopus subject areas

  • Molecular Biology
  • Genetics
  • Endocrinology


Dive into the research topics of 'Gene therapy for a mouse model of glucose transporter-1 deficiency syndrome'. Together they form a unique fingerprint.

Cite this